drugset
drugset / Trial / NCT02697552

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

NCT02697552 ↗

Phase 1 Completed 13 enrolled HUYABIO International, LLC.
NaSingle-groupOpen-labelTreatment

Summary

Phase 1, open-label, non-randomized, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HBI-8000 administered orally.

Timeline

Start
2014-03
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 30 mg Oral
Subject Tucidinostat Small molecule 40 mg Oral
Subject Tucidinostat Small molecule 50 mg Oral

Indications

non-Hodgkin lymphoma